Excused Juror Reveals Selection Process For Trump’s 'Hush-Money' Trial: 'All Have Prior Opinions' Authored by Jack Phillips via The Epoch...
I’m getting this question quite frequently now as more and more startups with recent funding rounds are looking to quickly expand.
Hospital officials in Finland are grappling with a surge in COVID-19 cases, as the spread of new and more contagious strains spread throughout the country
The Fed Just Keeps Getting More And More Dovish Via SchiffGold.com, Is Jerome Powell the most dovish Fed chair yet? Peter Schiff said he wasn’t when...
$100 Oil Bets Surge After Texas Turmoil Amid all the issues ignited in the Texas turmoil, and as oil prices roar to post-COVID highs, analysts across...
Many health experts believe that the Novavax COVID-19 vaccine candidate NVX-CoV237 offers potential advantages over competitors including Pfizer-BioNTech, Moderna, J&J, and AstraZeneca-Oxford.
Nvidia (NVDA) stock has been a winner in the pandemic era. The semiconductor giant represents a play on multiple trends including AI, cloud, gaming and AV/ADAS,...
On Twitter, Ryan Bourne links to a series of tweets by Ben Riley-Smith, the political editor of the Daily Telegraph, on Boris Johnson’s reopening plan. Ryan’s...
Prof. Thomas H. Epps, III named to American Institute for Medical and Biological Engineering College of Fellows Credit: Photo by Kathy F. Atkinson | Illustration by...
Biden To Sign Executive Order in Response to an Alarming Computer Chip Shortage That's Thrashing Carmakers
A number of central banks responded over the past week to rising bond yields driven higher by reflationary expectations. As a result, the risk that tantrums...
J&J COVID-19 Jab Is 72% Effective in US trial but more importantly 64% effective against South African Variant
Employers today often use perks to attract new talent in the form of discounts and deals, commuter funds, gym memberships, childcare, free lunches and more. But...
Europe’s drug regulator is evaluating South Korean drugmaker Celltrion’s Covid-19 antibody treatment, the third such drug against the disease to go under real-time review in the...
We’re in a volatile period right now, as stocks slipping after starting the year on a strong note. Big Tech, which boomed during the pandemic lockdowns...
The TJX Companies 4Q earnings were disappointing as the off-price retailer reported diluted earnings per share (EPS) of $0.27, which fell short of analysts’ estimates of...